A combination pharmaceutical composition for improving or treating follicular lymphoma and its application thereto.
The combined use of simvastatin and duveritase has addressed the incurable nature of existing treatments for follicular lymphoma, significantly inhibiting cell proliferation and apoptosis, improving survival rates, and providing a new treatment strategy.
CN119770495BActive Publication Date: 2026-06-30THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV
- Filing Date
- 2025-01-10
- Publication Date
- 2026-06-30
AI Technical Summary
Technical Problem
While existing treatments for follicular lymphoma have some effect, they are not curative. Some patients experience refractory or early relapse, leading to a shortened survival time, thus necessitating new treatment strategies.
Method used
The combined use of simvastatin and duveritine as active ingredients forms a combination drug composition that significantly improves or treats follicular lymphoma by inhibiting the proliferation of follicular lymphoma cells, inducing apoptosis, and inhibiting Pan-Kla expression.
Benefits of technology
It significantly inhibits the proliferation of follicular lymphoma cells, promotes apoptosis, reduces drug dosage, improves drug safety, and demonstrates in CDX mouse models that it can inhibit tumorigenesis and improve mouse survival rate.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN119770495B_ABST
Abstract
This invention relates to a combination pharmaceutical composition for improving or treating follicular lymphoma, characterized in that the active component of the combination pharmaceutical composition comprises a first active component and a second active component; the first active component is selected from simvastatin, any one or a combination of at least two of its pharmaceutically acceptable salts, isomers, solvates, and metabolites; the second active component is selected from duvelitaxel, any one or a combination of at least two of its pharmaceutically acceptable salts, isomers, solvates, and metabolites. This invention has found that simvastatin and duvelitaxel not only reduce the dosage of simvastatin or duvelitaxel and improve medication safety, but also have a more significant effect in improving or treating follicular lymphoma than simvastatin or duvelitaxel alone, exhibiting a synergistic effect.
Need to check novelty before this filing date? Find Prior Art